Annual CFO
-$224.84 M
-$1.22 M-0.54%
31 December 2023
Summary:
Sangamo Therapeutics annual cash flow from operations is currently -$224.84 million, with the most recent change of -$1.22 million (-0.54%) on 31 December 2023. During the last 3 years, it has fallen by -$394.72 million (-232.36%). SGMO annual CFO is now -232.36% below its all-time high of $169.88 million, reached on 31 December 2020.SGMO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$11.76 M
+$38.64 M+143.74%
30 September 2024
Summary:
Sangamo Therapeutics quarterly cash flow from operations is currently $11.76 million, with the most recent change of +$38.64 million (+143.74%) on 30 September 2024. Over the past year, it has increased by +$59.05 million (+124.86%). SGMO quarterly CFO is now -92.65% below its all-time high of $159.99 million, reached on 30 June 2020.SGMO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$114.33 M
+$59.05 M+34.06%
30 September 2024
Summary:
Sangamo Therapeutics TTM cash flow from operations is currently -$114.33 million, with the most recent change of +$59.05 million (+34.06%) on 30 September 2024. Over the past year, it has increased by +$117.03 million (+50.58%). SGMO TTM CFO is now -167.30% below its all-time high of $169.88 million, reached on 31 December 2020.SGMO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.5% | +124.9% | +50.6% |
| 3 y3 years | -232.4% | +119.8% | +38.1% |
| 5 y5 years | -715.2% | +130.3% | +30.2% |
SGMO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -232.4% | +3.6% | at high | +117.7% | at high | +51.9% |
| 5 y | 5 years | -232.4% | +3.6% | -92.7% | +117.2% | -167.3% | +51.9% |
| alltime | all time | -232.4% | +3.6% | -92.7% | +117.2% | -167.3% | +51.9% |
Sangamo Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $11.76 M(-143.7%) | -$114.33 M(-34.1%) |
| June 2024 | - | -$26.88 M(-44.8%) | -$173.38 M(-16.3%) |
| Mar 2024 | - | -$48.66 M(-3.7%) | -$207.21 M(-7.8%) |
| Dec 2023 | -$224.84 M(+0.5%) | -$50.54 M(+6.9%) | -$224.84 M(-2.8%) |
| Sept 2023 | - | -$47.29 M(-22.1%) | -$231.35 M(-2.7%) |
| June 2023 | - | -$60.71 M(-8.4%) | -$237.68 M(+2.9%) |
| Mar 2023 | - | -$66.30 M(+16.2%) | -$230.95 M(+3.3%) |
| Dec 2022 | -$223.63 M(-4.1%) | -$57.05 M(+6.4%) | -$223.63 M(+2.0%) |
| Sept 2022 | - | -$53.62 M(-0.7%) | -$219.29 M(-2.6%) |
| June 2022 | - | -$53.98 M(-8.5%) | -$225.09 M(+0.6%) |
| Mar 2022 | - | -$58.98 M(+11.9%) | -$223.68 M(-4.1%) |
| Dec 2021 | -$233.25 M(-237.3%) | -$52.71 M(-11.3%) | -$233.25 M(+26.2%) |
| Sept 2021 | - | -$59.42 M(+13.0%) | -$184.83 M(+100.2%) |
| June 2021 | - | -$52.57 M(-23.3%) | -$92.34 M(-176.8%) |
| Mar 2021 | - | -$68.55 M(+1496.0%) | $120.22 M(-29.2%) |
| Dec 2020 | $169.88 M(-217.6%) | -$4.29 M(-113.0%) | $169.88 M(+10.8%) |
| Sept 2020 | - | $33.07 M(-79.3%) | $153.35 M(+88.4%) |
| June 2020 | - | $159.99 M(-947.0%) | $81.41 M(-168.9%) |
| Mar 2020 | - | -$18.89 M(-9.3%) | -$118.17 M(-18.2%) |
| Dec 2019 | -$144.40 M(-495.1%) | -$20.82 M(-46.5%) | -$144.40 M(-11.8%) |
| Sept 2019 | - | -$38.87 M(-1.8%) | -$163.75 M(+7.4%) |
| June 2019 | - | -$39.59 M(-12.2%) | -$152.47 M(-1694.0%) |
| Mar 2019 | - | -$45.12 M(+12.3%) | $9.56 M(-73.8%) |
| Dec 2018 | $36.55 M(+227.0%) | -$40.16 M(+45.5%) | $36.55 M(-39.0%) |
| Sept 2018 | - | -$27.60 M(-122.5%) | $59.87 M(-16.6%) |
| June 2018 | - | $122.44 M(-775.2%) | $71.78 M(+1072.3%) |
| Mar 2018 | - | -$18.13 M(+7.7%) | $6.12 M(-45.2%) |
| Dec 2017 | $11.18 M(-117.0%) | -$16.84 M(+7.4%) | $11.18 M(-31.2%) |
| Sept 2017 | - | -$15.69 M(-127.6%) | $16.25 M(+13.2%) |
| June 2017 | - | $56.79 M(-534.2%) | $14.36 M(-124.5%) |
| Mar 2017 | - | -$13.08 M(+11.1%) | -$58.60 M(-11.1%) |
| Dec 2016 | -$65.88 M(+95.4%) | -$11.77 M(-33.1%) | -$65.88 M(+4.2%) |
| Sept 2016 | - | -$17.58 M(+8.7%) | -$63.22 M(+5.6%) |
| June 2016 | - | -$16.18 M(-20.5%) | -$59.84 M(+15.8%) |
| Mar 2016 | - | -$20.36 M(+123.6%) | -$51.69 M(+53.3%) |
| Dec 2015 | -$33.72 M(+494.2%) | -$9.10 M(-35.9%) | -$33.72 M(+23.4%) |
| Sept 2015 | - | -$14.20 M(+76.9%) | -$27.33 M(+44.6%) |
| June 2015 | - | -$8.03 M(+235.4%) | -$18.90 M(-2.8%) |
| Mar 2015 | - | -$2.39 M(-11.8%) | -$19.45 M(+242.7%) |
| Dec 2014 | -$5.67 M(-70.9%) | -$2.71 M(-53.0%) | -$5.67 M(+22.8%) |
| Sept 2014 | - | -$5.77 M(-32.7%) | -$4.62 M(+37.3%) |
| June 2014 | - | -$8.57 M(-175.3%) | -$3.37 M(+3860.0%) |
| Mar 2014 | - | $11.38 M(-786.7%) | -$85.00 K(-99.6%) |
| Dec 2013 | -$19.48 M(+141.1%) | -$1.66 M(-63.3%) | -$19.48 M(+10.7%) |
| Sept 2013 | - | -$4.51 M(-14.7%) | -$17.60 M(-3.5%) |
| June 2013 | - | -$5.29 M(-34.0%) | -$18.25 M(-3.8%) |
| Mar 2013 | - | -$8.02 M(-3695.5%) | -$18.97 M(+134.7%) |
| Dec 2012 | -$8.08 M | $223.00 K(-104.3%) | -$8.08 M(-2.7%) |
| Sept 2012 | - | -$5.16 M(-14.2%) | -$8.30 M(-13.6%) |
| June 2012 | - | -$6.01 M(-309.7%) | -$9.61 M(-13.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $2.87 M(>+9900.0%) | -$11.07 M(-57.3%) |
| Dec 2011 | -$25.89 M(+8.2%) | $2000.00(-100.0%) | -$25.89 M(-9.0%) |
| Sept 2011 | - | -$6.47 M(-13.4%) | -$28.47 M(+2.0%) |
| June 2011 | - | -$7.47 M(-37.5%) | -$27.92 M(-0.1%) |
| Mar 2011 | - | -$11.96 M(+365.1%) | -$27.93 M(+16.7%) |
| Dec 2010 | -$23.93 M(+290.0%) | -$2.57 M(-56.6%) | -$23.93 M(+145.8%) |
| Sept 2010 | - | -$5.92 M(-20.9%) | -$9.74 M(+15.6%) |
| June 2010 | - | -$7.49 M(-6.0%) | -$8.42 M(+19.6%) |
| Mar 2010 | - | -$7.96 M(-168.5%) | -$7.04 M(+14.7%) |
| Dec 2009 | -$6.14 M(-64.6%) | $11.62 M(-352.5%) | -$6.14 M(-49.2%) |
| Sept 2009 | - | -$4.60 M(-24.6%) | -$12.08 M(-2.1%) |
| June 2009 | - | -$6.10 M(-13.5%) | -$12.34 M(-23.0%) |
| Mar 2009 | - | -$7.05 M(-224.2%) | -$16.01 M(-7.7%) |
| Dec 2008 | -$17.34 M(+7.9%) | $5.68 M(-216.9%) | -$17.34 M(-38.3%) |
| Sept 2008 | - | -$4.86 M(-50.3%) | -$28.13 M(+18.1%) |
| June 2008 | - | -$9.78 M(+16.6%) | -$23.82 M(+24.7%) |
| Mar 2008 | - | -$8.39 M(+64.4%) | -$19.09 M(+18.8%) |
| Dec 2007 | -$16.07 M(+11.0%) | -$5.10 M(+829.3%) | -$16.07 M(+9.8%) |
| Sept 2007 | - | -$549.00 K(-89.1%) | -$14.63 M(-12.2%) |
| June 2007 | - | -$5.05 M(-5.7%) | -$16.67 M(+7.2%) |
| Mar 2007 | - | -$5.36 M(+46.1%) | -$15.55 M(+7.4%) |
| Dec 2006 | -$14.48 M(+255.8%) | -$3.67 M(+42.2%) | -$14.48 M(+173.0%) |
| Sept 2006 | - | -$2.58 M(-34.5%) | -$5.30 M(+7.0%) |
| June 2006 | - | -$3.94 M(-8.1%) | -$4.96 M(-0.4%) |
| Mar 2006 | - | -$4.29 M(-177.9%) | -$4.98 M(+22.3%) |
| Dec 2005 | -$4.07 M(-60.0%) | $5.51 M(-346.6%) | -$4.07 M(-64.1%) |
| Sept 2005 | - | -$2.23 M(-43.6%) | -$11.35 M(-8.2%) |
| June 2005 | - | -$3.96 M(+17.2%) | -$12.36 M(+8.2%) |
| Mar 2005 | - | -$3.38 M(+90.5%) | -$11.43 M(+12.5%) |
| Dec 2004 | -$10.16 M(+36.6%) | -$1.77 M(-45.3%) | -$10.16 M(+0.9%) |
| Sept 2004 | - | -$3.25 M(+7.1%) | -$10.08 M(+33.7%) |
| June 2004 | - | -$3.03 M(+43.3%) | -$7.54 M(+11.5%) |
| Mar 2004 | - | -$2.11 M(+25.3%) | -$6.76 M(-9.1%) |
| Dec 2003 | -$7.44 M(-16.2%) | -$1.69 M(+139.0%) | -$7.44 M(+51.4%) |
| Sept 2003 | - | -$706.00 K(-68.7%) | -$4.91 M(-31.4%) |
| June 2003 | - | -$2.25 M(-19.3%) | -$7.16 M(-21.3%) |
| Mar 2003 | - | -$2.79 M(-432.9%) | -$9.11 M(+2.6%) |
| Dec 2002 | -$8.88 M(+45.3%) | $839.00 K(-128.4%) | -$8.88 M(-18.6%) |
| Sept 2002 | - | -$2.95 M(-29.6%) | -$10.91 M(+15.8%) |
| June 2002 | - | -$4.20 M(+63.7%) | -$9.42 M(+15.3%) |
| Mar 2002 | - | -$2.56 M(+114.7%) | -$8.17 M(+33.8%) |
| Dec 2001 | -$6.11 M(+148.9%) | -$1.19 M(-18.6%) | -$6.11 M(+23.1%) |
| Sept 2001 | - | -$1.47 M(-50.2%) | -$4.96 M(+13.6%) |
| June 2001 | - | -$2.95 M(+489.2%) | -$4.37 M(+36.7%) |
| Mar 2001 | - | -$500.00 K(+900.0%) | -$3.20 M(+30.2%) |
| Dec 2000 | -$2.45 M(+2.3%) | -$50.00 K(-94.3%) | -$2.45 M(+2.1%) |
| Sept 2000 | - | -$872.00 K(-50.8%) | -$2.40 M(+56.9%) |
| June 2000 | - | -$1.77 M(-833.1%) | -$1.53 M(-733.1%) |
| Mar 2000 | - | $242.00 K | $242.00 K |
| Dec 1999 | -$2.40 M | - | - |
FAQ
- What is Sangamo Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual CFO year-on-year change?
- What is Sangamo Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly CFO year-on-year change?
- What is Sangamo Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM CFO year-on-year change?
What is Sangamo Therapeutics annual cash flow from operations?
The current annual CFO of SGMO is -$224.84 M
What is the all time high annual CFO for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual cash flow from operations is $169.88 M
What is Sangamo Therapeutics annual CFO year-on-year change?
Over the past year, SGMO annual cash flow from operations has changed by -$1.22 M (-0.54%)
What is Sangamo Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SGMO is $11.76 M
What is the all time high quarterly CFO for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly cash flow from operations is $159.99 M
What is Sangamo Therapeutics quarterly CFO year-on-year change?
Over the past year, SGMO quarterly cash flow from operations has changed by +$59.05 M (+124.86%)
What is Sangamo Therapeutics TTM cash flow from operations?
The current TTM CFO of SGMO is -$114.33 M
What is the all time high TTM CFO for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM cash flow from operations is $169.88 M
What is Sangamo Therapeutics TTM CFO year-on-year change?
Over the past year, SGMO TTM cash flow from operations has changed by +$117.03 M (+50.58%)